iNK-CD64/16A 细胞：ADCC 的一种有前途的方法？
iNK-CD64/16A cells: a promising approach for ADCC?
机构信息
Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, USA.
出版信息
Expert Opin Biol Ther. 2019 Dec;19(12):1229-1232. doi: 10.1080/14712598.2019.1667974. Epub 2019 Sep 19.
Abstract
: ADCC by natural killer (NK) cells is a key mechanism for several clinically successful tumor-targeting therapeutic antibodies. Most patients, however, have limited responses to this therapy and/or develop resistance. NK cells exclusively recognize IgG by their low-affinity FcγR CD16A.: We describe in this editorial a novel recombinant FcγR that consists of CD64, the only high affinity IgG receptor, and the transmembrane and cytoplasmic regions of CD16A, a potent activating receptor. CD64/16A was expressed in engineered iPSCs that were differentiated into NK cells (referred to as iNK cells).: iNK-CD64/16A cells in combination with therapeutic antibodies provide a universal tumor antigen targeting approach and potential off-the-shelf cell therapy to treat various malignancies.
摘要
自然杀伤 (NK) 细胞通过抗体依赖性细胞毒性作用 (ADCC) 是几种临床成功的肿瘤靶向治疗抗体的关键机制。然而，大多数患者对这种治疗的反应有限，或者产生耐药性。NK 细胞通过其低亲和力 FcγR CD16A 特异性识别 IgG。: 在这篇社论中，我们描述了一种新型的重组 FcγR，它由唯一的高亲和力 IgG 受体 CD64 和 CD16A 的跨膜和胞质区组成，CD16A 是一种有效的激活受体。CD64/16A 在工程 iPSC 中表达，这些 iPSC 分化为 NK 细胞（称为 iNK 细胞）。: iNK-CD64/16A 细胞与治疗性抗体联合使用，为治疗各种恶性肿瘤提供了一种通用的肿瘤抗原靶向方法和潜在的现货细胞治疗方法。
相似文献
1
iNK-CD64/16A cells: a promising approach for ADCC?
Expert Opin Biol Ther. 2019 Dec;19(12):1229-1232. doi: 10.1080/14712598.2019.1667974. Epub 2019 Sep 19.
2
iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma.
Front Immunol. 2024 Jul 19;15:1407567. doi: 10.3389/fimmu.2024.1407567. eCollection 2024.
3
Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Front Immunol. 2018 Dec 6;9:2873. doi: 10.3389/fimmu.2018.02873. eCollection 2018.
4
iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.
J Immunother Cancer. 2023 Dec 6;11(12):e007280. doi: 10.1136/jitc-2023-007280.
5
Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
Blood. 2020 Feb 6;135(6):399-410. doi: 10.1182/blood.2019000621.
6
Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
Front Immunol. 2022 Feb 24;13:841859. doi: 10.3389/fimmu.2022.841859. eCollection 2022.
7
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers.
MAbs. 2024 Jan-Dec;16(1):2381261. doi: 10.1080/19420862.2024.2381261. Epub 2024 Jul 24.
8
Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Oncotarget. 2017 Jun 6;8(23):37128-37139. doi: 10.18632/oncotarget.16201.
9
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.
10
Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
Cytotherapy. 2024 Mar;26(3):252-260. doi: 10.1016/j.jcyt.2023.11.009. Epub 2023 Dec 19.
引用本文的文献
1
Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1-infected CD4+ T cells by ADCC.
J Immunol. 2025 Feb 1;214(2):253-264. doi: 10.1093/jimmun/vkae028.
2
Decorin-armed oncolytic adenovirus promotes natural killers (NKs) activation and infiltration to enhance NK therapy in CRC model.
Mol Biomed. 2024 Nov 1;5(1):48. doi: 10.1186/s43556-024-00212-z.
3
iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma.
Front Immunol. 2024 Jul 19;15:1407567. doi: 10.3389/fimmu.2024.1407567. eCollection 2024.
4
Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective.
Biomark Res. 2024 Jul 17;12(1):66. doi: 10.1186/s40364-024-00610-z.
5
iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.
J Immunother Cancer. 2023 Dec 6;11(12):e007280. doi: 10.1136/jitc-2023-007280.
6
Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
Immunology. 2023 Oct;170(2):202-213. doi: 10.1111/imm.13662. Epub 2023 May 22.
7
The effects of maternal anti-alpha-enolase antibody expression on the brain development in offspring.
Clin Exp Immunol. 2022 Dec 15;210(2):187-198. doi: 10.1093/cei/uxac086.
8
Antiviral Cell Products against COVID-19: Learning Lessons from Previous Research in Anti-Infective Cell-Based Agents.
Biomedicines. 2022 Apr 7;10(4):868. doi: 10.3390/biomedicines10040868.
9
Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
Front Immunol. 2022 Feb 24;13:841859. doi: 10.3389/fimmu.2022.841859. eCollection 2022.
10
Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review).
Int J Oncol. 2022 Feb;60(2). doi: 10.3892/ijo.2022.5302. Epub 2022 Jan 4.
本文引用的文献
1
Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy.
Antib Ther. 2018 Jun 24;1(1):7-12. doi: 10.1093/abt/tby002. eCollection 2018 Jun.
2
Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy.
J Leukoc Biol. 2019 Jun;105(6):1297-1303. doi: 10.1002/JLB.2MR1218-501R. Epub 2019 Feb 20.
3
Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Front Immunol. 2018 Dec 6;9:2873. doi: 10.3389/fimmu.2018.02873. eCollection 2018.
4
Universal CARs, universal T cells, and universal CAR T cells.
J Hematol Oncol. 2018 Nov 27;11(1):132. doi: 10.1186/s13045-018-0677-2.
5
Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
Semin Immunopathol. 2019 Jan;41(1):59-68. doi: 10.1007/s00281-018-0721-x. Epub 2018 Oct 25.
6
Mechanisms of inside-out signaling of the high-affinity IgG receptor FcγRI.
Sci Signal. 2018 Jul 24;11(540):eaaq0891. doi: 10.1126/scisignal.aaq0891.
7
Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells.
J Cell Biol. 2018 Sep 3;217(9):3267-3283. doi: 10.1083/jcb.201712085. Epub 2018 Jul 2.
8
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22.
9
Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells.
Sci Rep. 2017 Jun 23;7(1):4204. doi: 10.1038/s41598-017-04147-0.
10
Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells.
PLoS One. 2015 Mar 27;10(3):e0121788. doi: 10.1371/journal.pone.0121788. eCollection 2015.
Zotero 插件